Answers are grounded in this paper and cite their sources.
Untargeted metabolomics shows that SPP1 influences metabolism in adipocytes, suggesting potential therapeutic targets.
Secreted phosphoprotein 1 (SPP1), also known as osteopontin (OPN), is a multifunctional secreted factor implicated in inflammatory remodeling of adipose tissue. Here, we applied untargeted liquid chromatography–mass spectrometry (LC–MS)-based metabolomics to examine how different concentrations of SPP1 influence metabolism in differentiated 3T3-L1 adipocytes. We found that low-dose SPP1 (100 ng/mL) was associated with more pronounced intracellular metabolic remodeling than higher-dose SPP1 (500 ng/mL). Multivariate analyses, including principal component analysis (PCA), partial least squares–discriminant analysis (PLS-DA), and sparse PLS-DA, revealed a distinct metabolic profile in the low-dose group, whereas the high-dose group showed a comparatively attenuated metabolic response. Pathway enrichment analysis identified alterations in carbohydrate- and amino acid-related metabolic networks, including the pentose phosphate pathway; pentose and glucuronate interconversions; and alanine, aspartate, and glutamate metabolism. In contrast, higher-dose SPP1 was associated with selective induction of matrix metalloproteinase-12 (MMP-12), suggesting the engagement of remodeling-associated responses at elevated SPP1 levels. Together, these findings identify SPP1 as a modulator of metabolic programs in mature adipocytes and highlight its capacity to influence intracellular metabolic remodeling.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: